Liver-Screen® – home test for liver function (ALT and AST)
Liver-Screen® is a CE-marked, clinically validated rapid test that allows you to check the levels of transaminases (ALT and AST) in a drop of capillary blood from the finger. These enzymes are released when liver cells are under stress or affected by factors such as hepatitis, alcohol, medications, obesity, diabetes or hypertension. The test shows in 10 minutes whether the level is above the normal limit (80 IU/L). The liver is central to detoxification, energy metabolism and protein synthesis, and symptoms such as dark urine, pale stools, fatigue, loss of appetite, yellowing of the skin/eyes, bloating and weakness can be signs of imbalance. Liver-Screen® makes it easy to get an early indication at home, without waiting at the GP. 🩸🧪

Brief description
Liver-Screen® is a quick and user-friendly self-test that measures elevated ALT/AST (>80 IU/L). A positive result means that you should contact a doctor for further investigation. Accuracy 89.2%, CE-IVD approved and used by healthcare professionals in Europe. ⚕️

Health effects
Liver-Screen® provides insight into liver enzymes that reflect the liver's reaction to stress. The test does not replace medical diagnosis, but serves as an early warning tool.
• Helps to detect enzyme release during liver stress - useful for symptoms or lifestyle stress.
• Suitable for risk factors such as obesity, alcohol use, diabetes or use of drugs that burden the liver.
• Provides rapid clarification of symptoms such as yellowing, reduced appetite or extreme fatigue.
No EFSA-approved health claims apply to diagnostic tools.

Top 2 main features
• Detects elevated ALT/AST (>80 IU/L) using specific antibodies calibrated against the IFCC method.
• Early screening of liver stress which provides the basis for further tests such as bilirubin, ALP, LDH and GGT.

A surprising or lesser-known health effect
Elevated transaminases can occur after intense exercise or when overweight, without the presence of disease. This makes the test useful for detecting lifestyle-related imbalances early. 🏃♂️🔥

Technical details and specifications
Liver-Screen® is an immunochromatographic lateral flow test with two red test lines (ALT and AST) in the T-zone and one blue control line in the C-zone.
• Enzymes that are detected: ALT and AST
• Cut-off level: 80 IU/L
• Sensitivity/correlation: 89.2% (95% CI 84.8–92.7%)
• Sample material: capillary blood
• Reading time: 10 minutes
• Certification: CE-IVD, ISO 13485
• Storage: 4–30 °C
• Shelf life: 24 months
• Use: home and professional setting

Ingredients list
The test contains immunological reagents (antibodies), buffer and dyes. No nutrients or supplements.

Recommended use
• Prepare the test cassette, pipette and the buffer bottle.
• Clean your fingertip and use the lancet to draw a drop of blood.
• Allow the pipette to draw blood up to the mark without squeezing.
• Transfer the blood to the test well and wait 30-40 seconds.
• Add 4 drops of buffer at 2-3 second intervals.
• Read the result after 10 minutes (not after 15 minutes).
Can be performed at any time for symptoms or routine check-ups.

Result interpretation
• Positive: One or two red lines + blue control line → ALT and/or AST >80 IU/L. Contact a doctor.
• Negative: Blue C line only → normal values.
• Invalid: Missing blue C line → repeat with new test.
Color intensity does not affect the result. The lines must be clear and complete.

Questions and answers
• How does the test work? Liver cells release transaminases into the blood when damaged. The test detects elevated levels using specific antibodies.
• When should I test? For symptoms, after stress, or as screening for risk factors.
• Could the result be wrong? Yes, if the test material is moistened or the wrong amount of blood is used.
• What do I do if I test positive? Contact your GP for further tests (ALP, GGT, bilirubin, LDH).
• Is the test accurate? Yes, it has 89.2% correlation with laboratory standards, but medical judgment is always necessary.

Reservation
Liver-Screen® is a medical IVD screening tool for adults. The test should not replace medical examinations. A positive test always requires follow-up with a doctor. A negative test does not rule out disease. Pregnant, breastfeeding or people with medical conditions should consult a doctor before use. Keep out of the reach of children.

Freedom of expression and right to information
Uno Vita reserves the right to share research and health information within the framework of national and international laws on freedom of expression, including UN Human Rights Article 19, ICCPR Article 19, the Constitution §100 and the US First Amendment.

Scientific references

1. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-1081.
2. Kwo PY, et al. American Association for the Study of Liver Diseases Practice Guidance on the role of transaminases in the diagnosis and management of liver disease. Hepatology. 2018;68(3):1382-1395.
3. Dufour DR, et al. Clinical Biochemistry Review: Liver Function Tests. Clin Biochem Rev. 2000;21(4):113-130.
4. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). IFCC Methods for the Measurement of Catalytic Concentration of Enzymes. Clin Chem Lab Med. 2011;49(9):1501-1520.
5. Prati D, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10.
6. Swiss Point of Care Validation Report LIVER-Screen® – Clinical Performance Study 2023.
7. Norwegian Institute of Public Health. Liver health and transaminases in Norway 2025.
8. Clark JM, et al. Serum aminotransferase levels and mortality risk among US adults. Hepatology. 2007;46(2):529-537.
9. Giannini EG, et al. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367-379.
10. McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J. 2016;15:817-828.
11. European Medicines Agency (EMA). Guideline on the evaluation of medicinal products in the treatment of primary biliary cirrhosis (PBC). 2012.
12. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update. Hepatology. 2018;68(5):1720-1733.
13. World Health Organization (WHO). Guidelines for the prevention, diagnosis, and management of chronic hepatitis B infection. 2015.
14. Lilienfeld-Toal H, et al. Elevated liver enzymes: What is the prognostic value? Dtsch Arztebl Int. 2014;111(29-30):508-516.
15. Valenti L, et al. Elevated alanine aminotransferase in asymptomatic adults: Frequency and clinical significance. Hepatology. 2005;42(4):A1044.
16. Ruhl CE, Everhart JE. Determinants of the association of elevated alanine aminotransferase in the US population. Gastroenterology. 2006;131(5):1493-1502.
17. Contoil M, et al. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A review. Hepatology. 2018;67(5):1753-1765.
18. Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
19. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181.
20. Rehm J, et al. Alcohol consumption and mortality in Europe: A systematic review and meta-analysis. Lancet. 2017;389(10071):2224-2235.
21. Angulo P, et al. Liver transplantation for nonalcoholic steatohepatitis: The way forward. Hepatology. 2015;62(4):1189-1191.

Disclaimer
Uno Vita uses advanced artificial intelligence in the development of information and texts. We are not responsible for any errors due to technological or human inaccuracies. All information must be evaluated critically. The product does not diagnose disease and does not replace medical advice. All use is at your own risk.